Paclitaxel and Carboplatin With or Without Bevacizumab in Treating Patients With Stage II, Stage III, or Stage IV Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
University of Chicago
Grupo Español de Investigación en Cáncer de Ovario
Merck Sharp & Dohme LLC
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AbbVie
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Shattuck Labs, Inc.
National Cancer Institute (NCI)
Mayo Clinic
National Cancer Institute (NCI)
Mayo Clinic
Pfizer
Transgene
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Wake Forest University Health Sciences
Bristol-Myers Squibb
Corcept Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Mural Oncology, Inc
AbbVie
Masonic Cancer Center, University of Minnesota
Herlev Hospital
pharmaand GmbH
Roswell Park Cancer Institute
Universitaire Ziekenhuizen KU Leuven
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
NRG Oncology
Numab Therapeutics AG
Thomas Jefferson University
University of Pennsylvania
University of Pennsylvania
Shattuck Labs, Inc.
Mayo Clinic
Roswell Park Cancer Institute
Pfizer
Mundipharma Research Limited